Organisation paid for research Program year 2023 Source: CMS Open Payments

Broome Oncology, LLC

Neither a doctor nor a teaching hospital

Research payments

$393,158

139 payments

Through program year 2023, Broome Oncology, LLC is reported as receiving $393,158 in research payments, across 139 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $11,995 5
2022 Research $31,854 10
2021 Research $32,466 4
2020 Research $81,288 22
2019 Research $235,554 98

Breakdown

Who paid Research payments · program years 2019–2023
  1. Merck Sharp & Dohme Corporation $363,375 131 payments
  2. Genentech, Inc. $16,928 2 payments
  3. MorphoSys AG $12,855 6 payments
Studies the money was for Research payments · program years 2019–2023
  1. A Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy Pembrolizumab MK 3475 with or without Lenvatinib E7080,MK 7902 as First line Intervention in Participants with Metastatic Nonsquamous Non small Cell Lung Cancer LEAP 006 $128,539 16 payments
  2. A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC $117,890 94 payments
  3. A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC $59,544 5 payments
  4. A Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy Pembrolizumab MK 3475 with or without Lenvatinib E7080,MK 7902 as First-line Intervention in Participants with Metastatic Nonsquamous Non small Cell Lung Cancer LEAP-006 $32,151 4 payments
  5. Atezolizumab Carboplatin Etoposide Tiragolumab Or Placebo in 1L Es SCLC $16,928 2 payments
  6. : A Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK 3475) with or without Lenvatinib (E7080/MK 7902) as First line Intervention in Participants with Metastatic Nonsquamous Non small Cell Lung Cancer (LEAP 006) $16,246 1 payment
  7. A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) $9,987 3 payments
  8. A Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy Pembrolizumab MK 3475 with or without Lenvatinib E7080,MK 7902 as First line Intervention in Participants with Metastatic Nonsquamous Non small Cell Lung Cancer LEAP 006 $6,168 8 payments
  9. A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind $2,868 3 payments
  10. A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 $1,714 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record